Track the UNITED THERAPEUTICS CORPORATION stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Market capitalisation: €21.9bn. The latest transaction was disclosed on 3 September 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: PAUL MAHON. All data is openly available.
10
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate UNITED THERAPEUTICS CORPORATION Buy (bullish), based on 12 analysts. Average price target: US$664.33.
31Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 2,249 of 29,064 companies
76.1
score / 100
Value
61
Quality
91
FCF yld4.7%
Earn yld6.1%
EV/EBITDA12.2x
ROE19%
Gross mgn88%
Net mgn42%
Debt/EBITDA0.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.